Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer

Cancer

Volumn 113, Issue 4, 2008, Pages 799-807

  Han, Ji Youn ^a   Geon, Kook Lee ^a   Dae, Ho Jang ^a   Sung, Young Lee ^a   Jin, Soo Lee ^a  

^a National Cancer Center   (South Korea)

Author keywords

MDM2; Nonsmall cell lung cancer; NSCLC; p53 expression

Indexed keywords

CISPLATIN; GEMCITABINE; IRINOTECAN; NAVELBINE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MDM2 SNP309 GENE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; P53 CODON 72 GENE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SEX RATIO; SMOKING HABIT; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CODON; FEMALE; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 50249125475     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23668     Document Type: Article

References (48)

1. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001;114:4139-4140.
2. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992;326:1309-1315.
3. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-456.
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
6. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96-107.
7. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-1245.
8. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362:857-860.
9. Fang S, Jensen JP, Ludwig RL, et al. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000;275:8945-8951.
10. Grossman SR, Deato ME, Brignone C, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003;300:342-344.
11. Landers JE, Haines DS, Strauss JF 3rd, et al. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene. 1994;9:2745-2750.
12. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453-3459.
13. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602.
14. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65:5481-5484.
15. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein. Thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999;59:1-7.
16. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47-54.
17. Buchman VL, Chumakov PM, Ninkina NN, et al. A variation in the structure of the protein-coding region of the human p53 gene. Gene. 1988;70:245-252.
18. Harris N, Brill E, Shohat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986;6:4650-4656.
19. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092-1100.
20. Baptiste N, Friedlander P, Chen X, et al. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002;21:9-21.
21. Dumont P, Leu JI, Della Pietra AC 3rd, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357-365.
22. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wildtype p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23:3328-3337.
23. Han JY, Lim HS, Lee DH, et al. Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006;106:873-880.
24. Lee JS, Lee DH, Han JY, et al. Randomized phase II crossover sequential chemotherapy trial of irinotecan/cisplatin vs. gemcitabine/vinorelbine in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer. Proc Am Soc Clin Oncol. 2006;24:7134.
25. Xu Y, Yao L, Ouyang T, et al. p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005;11:7328-7333.
26. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13:4123-4129.
27. Wang YC, Lin RK, Tan YH, et al. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol. 2005;23:154-164.
28. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res. 2005;11:2502-2509.
29. Nelson HH, Wilkojmen M, Marsit CJ, et al. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005;26:1770-1773.
30. Chen L, Agrawal S, Zhou W, et al. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A. 1998;95:195-200.
31. Ahrendt SA, Chow JT, Yang SC, et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res. 2000;60:3155-3159.
32. Skaug V, Ryberg D, Kure EH, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res. 2000;6:1031-1037.
33. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000;6:4055-4063.
34. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol. 2001;19:448-457.
35. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240-5247.
36. Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprotein in non-small-cell lung cancer, a favorable prognostic factor. J Clin Oncol. 1995;13:1893-1903.
37. Passlick B, Izbicki JR, Häussinger K, et al. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1995;109:1205-1211.
38. Fokkema E, Timens W, de Vries EG, et al. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer. 2006;52:241-247.
39. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992;52:4828-4831.
40. Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer. 1995;76:2457-2463.
41. McLaren R, Kuzu I, Dunnill M, et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer. 1992;66:735-738.
42. Leach FS, Tokino T, Meltzer R et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53(10 suppl):2231-2234.
43. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80-83.
44. He J, Zhou F, Shao K, et al. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer. 2007;56:51-58.
45. Aikawa H, Sato M, Fujimura S, et al. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med 2000;5:631-633.
46. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer. 1997;75:1302-1308.
47. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol. 2007;25:2243-2247.
48. Klein C and Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 2004;91:1415-1419.